{
    "clinical_study": {
        "@rank": "166685", 
        "arm_group": [
            {
                "arm_group_label": "Group 1: D961H sachet 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "Age: \u22651 year Weight: <20 kg"
            }, 
            {
                "arm_group_label": "Group 2: D961H capsule 10mg", 
                "arm_group_type": "Experimental", 
                "description": "Age: \u22651 year to 11years Weight: \u226520 kg"
            }, 
            {
                "arm_group_label": "Group 3: D961H capsule 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Age: \u22651 year to 11years Weight: \u226520 kg"
            }, 
            {
                "arm_group_label": "Group 4: D961H capsule 10 mg", 
                "arm_group_type": "Experimental", 
                "description": "Age: 12 to 14 years Weight: \u226520 kg"
            }, 
            {
                "arm_group_label": "Group 5: D961H capsule 20 mg", 
                "arm_group_type": "Experimental", 
                "description": "Age: 12 to 14 years Weight: \u226520 kg"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the safety, pharmacokinetics, pharmacodynamics and\n      efficacy of repeated once daily oral administration of D961H 10 mg and D961H 20 mg in\n      Japanese paediatric patients aged 1 to 14 years old who either have a diagnosis of or are\n      suspected to have gastric ulcer (GU), duodenal ulcer (DU), anastomotic ulcer (AU),\n      non-erosive reflux esophagitis disease (NERD), reflux esophagitis (RE) or Zollinger-Ellison\n      syndrome."
        }, 
        "brief_title": "A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gastric Ulcer (GU)", 
            "Duodenal Ulcer (DU)", 
            "Anastomotic Ulcer (AU)", 
            "Non-erosive Reflux Esophagitis Disease (NERD)", 
            "Reflux Esophagitis (RE)", 
            "Zollinger-Ellison Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Duodenal Ulcer", 
                "Esophagitis", 
                "Esophagitis, Peptic", 
                "Gastroesophageal Reflux", 
                "Stomach Ulcer", 
                "Ulcer", 
                "Zollinger-Ellison Syndrome", 
                "Gastrinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of signed written informed consent from the patient's guardian\n\n          -  Patients aged \u2265 1 year to 14 years old\n\n          -  Patients who have a diagnosis of or suspected to have GU, DU, AU, NERD, RE or\n             Zollinger-Ellison syndrome.\n\n        Exclusion Criteria:\n\n          -  Patients less than 10 kg in weight.\n\n          -  Use of any other investigational compounds or participations in another clinical\n             trial within 4 weeks prior to the randomisation/registration.\n\n          -  Significant clinical illness within 4 weeks prior to the registration\n\n          -  Presence of hepatic diseases or other conditions that could interfere with evaluation\n             of the study as judged by the investigators.\n\n          -  Positive for pregnancy test by urinary or lactation for post-menarchal females.\n\n          -  Previous total gastrectomy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153398", 
            "org_study_id": "D961TC00002", 
            "secondary_id": "26-022"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1: D961H sachet 10 mg", 
                "intervention_name": "D961H sachet 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 2: D961H capsule 10mg", 
                    "Group 4: D961H capsule 10 mg"
                ], 
                "intervention_name": "D961H capsule 10mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group 3: D961H capsule 20 mg", 
                    "Group 5: D961H capsule 20 mg"
                ], 
                "intervention_name": "D961H capsule 20 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastric ulcer (GU)", 
            "Duodenal ulcer (DU)", 
            "Anastomotic ulcer (AU)", 
            "Non-erosive reflux esophagitis disease (NERD)", 
            "Reflux esophagitis (RE)", 
            "Zollinger-Ellison syndrome"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suzaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ureshino-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "5", 
        "official_title": "An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases", 
        "other_outcome": {
            "description": "Assessment of endoscopic presence/absence of GU, DU, AU or RE according to the EGD findings", 
            "measure": "Esophagogastroduodenoscopy(EGD) findings", 
            "safety_issue": "No", 
            "time_frame": "Pre dose and after at least 5 days of repeated dose"
        }, 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Keiko Komuro", 
            "phone": "+81-3-6268-2740"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety of D961H in terms of a panel of safety measures: adverse events, physical examination, vital signs and laboratory variables", 
            "safety_issue": "Yes", 
            "time_frame": "From baseline to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153398"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacodynamic variabilities by assessment of the percentages of time with intragastric pH >4 and pH>3 (percent of the time)", 
                "safety_issue": "No", 
                "time_frame": "Pre dose (Week 0) and after at least 5 days of repeated dose (Week 1,4 or 8)"
            }, 
            {
                "description": "AUCtau, AUC0-t, Cmax, tmax, and t1/2 (For all) CL/F, Vz/F (For esomeprazole only) AUCtau:Area under the curve during a dosing interval, AUC0-t:AUC from time zero to time of last quantifiable concentration, Cmax:Maximum plasma concentration,tmax: Time to reach maximum plasma concentration, t\u00bd: Elimination half-life, CL/F: Apparent total clearance and Vz/F: Apparent volume of distribution during terminal phase", 
                "measure": "Pharmacokinetics of esomeprazole and its metabolites by assessment of AUCtau, AUC0-t, Cmax, tmax, t\u00bd, CL/F and Vz/F", 
                "safety_issue": "No", 
                "time_frame": "Pre dose (Week 0) and after at least 5 days of repeated dose (Week 1,4 or 8)"
            }, 
            {
                "measure": "The number of disappearance or aggravation of gastrointestinal symptom assessed by the investigators and the patient diaries", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 8 weeks"
            }, 
            {
                "measure": "Pharmacodynamic variabilities by assessment of median intragastric pH during 12 hours", 
                "safety_issue": "No", 
                "time_frame": "Pre dose (Week 0) and after at least 5 days of repeated dose (Week 1,4 or 8)"
            }, 
            {
                "measure": "The percentage of disappearance or aggravation of gastrointestinal symptom assessed by the investigators and the patient diaries", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 8 weeks"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}